BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 31699993)

  • 1. Craniopharyngioma.
    Müller HL; Merchant TE; Warmuth-Metz M; Martinez-Barbera JP; Puget S
    Nat Rev Dis Primers; 2019 Nov; 5(1):75. PubMed ID: 31699993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Craniopharyngioma in Pediatrics and Adults.
    Piloni M; Gagliardi F; Bailo M; Losa M; Boari N; Spina A; Mortini P
    Adv Exp Med Biol; 2023; 1405():299-329. PubMed ID: 37452943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary Biological Insights and Clinical Management of Craniopharyngioma.
    Apps JR; Muller HL; Hankinson TC; Yock TI; Martinez-Barbera JP
    Endocr Rev; 2023 May; 44(3):518-538. PubMed ID: 36574377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
    Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
    [No Abstract]   [Full Text] [Related]  

  • 5. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
    Erfurth EM
    J Intern Med; 2023 Sep; 294(3):269-280. PubMed ID: 37424210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
    Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
    Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Craniopharyngiomas.
    Hamblin R; Tsermoulas G; Karavitaki N
    Presse Med; 2021 Dec; 50(4):104078. PubMed ID: 34688870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
    Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
    J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood-onset Craniopharyngioma.
    Otte A; Müller HL
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e3820-e3836. PubMed ID: 34086900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological Behaviour of Craniopharyngiomas.
    Martinez-Barbera JP; Andoniadou CL
    Neuroendocrinology; 2020; 110(9-10):797-804. PubMed ID: 32126562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
    Robinson LC; Santagata S; Hankinson TC
    Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
    He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
    Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
    Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
    Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
    Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
    Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular pathogenesis of craniopharyngiomas.
    Campanini ML; Almeida JP; Martins CS; de Castro M
    Arch Endocrinol Metab; 2023 Mar; 67(2):266-275. PubMed ID: 36748936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
    Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
    Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis.
    Preda V; Larkin SJ; Karavitaki N; Ansorge O; Grossman AB
    Endocr Pathol; 2015 Mar; 26(1):1-8. PubMed ID: 25355426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma.
    Scagliotti V; Avagliano L; Gualtieri A; Graziola F; Doi P; Chalker J; Righini A; Korbonits M; Bulfamante G; Jacques TS; Massa V; Gaston-Massuet C
    Pituitary; 2016 Feb; 19(1):50-6. PubMed ID: 26350256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.